Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Methotrexate Gold Nanocarriers: Loading and Release Study. Its Activity in Colon and Lung Cancer Cells

Version 1 : Received: 15 November 2020 / Approved: 16 November 2020 / Online: 16 November 2020 (17:38:03 CET)

How to cite: Álvarez-González, B.; Rozalen, M.; Fernández-Perales, M.; Álvarez, M.A.; Sánchez-Polo, M. Methotrexate Gold Nanocarriers: Loading and Release Study. Its Activity in Colon and Lung Cancer Cells. Preprints 2020, 2020110440 (doi: 10.20944/preprints202011.0440.v1). Álvarez-González, B.; Rozalen, M.; Fernández-Perales, M.; Álvarez, M.A.; Sánchez-Polo, M. Methotrexate Gold Nanocarriers: Loading and Release Study. Its Activity in Colon and Lung Cancer Cells. Preprints 2020, 2020110440 (doi: 10.20944/preprints202011.0440.v1).

Abstract

In the present study the synthesis of gold nanoparticles (AuNPs) loaded with methotrexate (MTX) has been carried out in order to obtain controlled size and monodispersed nanocarriers, around 20nm. Characterization study shows metallic AuNPs with MTX polydispersed on the surface. MTX is linked by a replacement of citrate by the MTX carboxyl group. The drug release profiles showed faster MTX release when it is conjugated, which leads to the best control of plasma concentration. Also, the enhanced release observed at pH 5 could take advantage of the pH gradients that exist in tumor microenvironments to achieve high local drug concentrations. AuNPs-MTX conjugates were tested by flow cytometry against lung (A-549) and colon (HTC-116) cancer cell lines. Results for A-549 showed a lighter dose-response effect than for colon cancer ones. This could be related to the presence of folate receptors in line HTC-116 on the contrary than line A-549, supporting the specific uptake of folate-conjugated AuNPs-MTX by folate receptor positive tumor cells. Conjugates exhibited considerably higher cytotoxic effects compared with the effects of equal doses of free MTX. Anexin V-PI test sustain as cell death mechanism apoptosis, which is normally disabled in cancer cells.

Subject Areas

Au nanoparticles; nanocarriers; methotrexate; anticancer drug; chemotherapeutics; controlled release

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.